UBC® Rapid | IDL Biotech
IDL Biotech


UBC® Rapid

UBC® Rapid  is a powerful Doctors-office test (Point-of-Care), for both primary diagnosis and monitoring of bladder cancer. The test specifically measures soluble fragments of cytokeratin 8 and 18 in urine samples. It can easily be performed by a nurse or a technician with minimal training and the results are obtained within 10 minutes. Elevated amounts of cytokeratin protein fragments are present in the urine of many individuals with bladder cancer, even at early stages of the disease.
UBC® Rapid  shall be used for quantitative determination in combination with the POC-reader, concile® Ω100.


– The only quantitative POC test platform for urine based detection of bladder cancer.
– Easy and rapid to perform – result within 10 minutes
– Works in haematuria

Find more information

UBC® Rapid  is a powerful diagnostic parameter in primary diagnosis and follow-up of bladder cancer, especially for papillary non-invasive high-grade tumors and carcinoma in situ (CIS).

Clinical evaluation

UBC® Rapid performs better than urine cytology in many patients due to improved sensitivity and the combination of UBC® Rapid  and cytology enables detection of additional tumors as opposed to cytology alone.

German study recommends UBC® Rapid to be added in the diagnostics and follow-up of high risk bladder cancer

International Journal of Molecular Sciences has published a study on UBC® Rapid. In total 530 urine samples was included in the multicenterstudy.

6 things you need to know about Bladder Cancer

New interesting findings for the tumor marker UBC® Rapid

Result from a new German multicenter study

Positive results for UBC Rapid in Clinical study

Evaluation of bladder cancer with point-of-care (POC) tests depends on the detection of bladder cancer associated proteins in urine samples.

Positive results for UBC® Rapid in a Swedish multicenter study

The study published in Scandinavian Journal of Urology (https://www.ncbi.nlm.nih.gov/pubmed/28422550) was conducted at four Swedish hospitals; Uppsala University Hospital, Danderyds hospital, Enköping Hospital and Umeå University Hospital. Principal investigators was Assoc. Prof Amir Sherif, Umeå University.

Positive results for UBC® Rapid in an Austrian study

International Journal of Medical Sciences has published an Austrian study with UBC® Rapid performed at the Department of Urology, Medical University of Innsbruck. Urinary samples were analyzed by cytology, UBC® Rapid and NMP22 BladderChek® test.

UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours

Results from a published multicenter study

IDL Biotech

Skip this intro